Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
Price charts only tell part of the story. Our team at StockStory evaluates each company's underlying fundamentals to separate temporary setbacks from structural declines. That said, here is one stock where you should be greedy instead of fearful and two where the skepticism is well-placed.
Two Stocks to Sell:
Angi (ANGI)
One-Month Return: -38.9%
Created by IAC’s mergers of Angie’s List and HomeAdvisor, ANGI (NASDAQ: ANGI) operates the largest online marketplace for home services in the US.
Why Do We Think Twice About ANGI?
- Struggled with new customer acquisition as its service requests averaged 21.3% declines
- Demand will likely be soft over the next 12 months as Wall Street’s estimates imply tepid growth of 1.1%
- Highly competitive market means it’s on the never-ending treadmill of sales and marketing spend
Angi’s stock price of $7.80 implies a valuation ratio of 3.7x forward EV/EBITDA. Dive into our free research report to see why there are better opportunities than ANGI.
AECOM (ACM)
One-Month Return: +0.9%
Founded in 1990 when a group of engineers from five companies decided to merge, AECOM (NYSE: ACM) provides various infrastructure consulting services.
Why Are We Cautious About ACM?
- Demand cratered as it couldn’t win new orders over the past two years, leading to an average 4% decline in its backlog
- Subpar operating margin of 4.8% constrains its ability to invest in process improvements or effectively respond to new competitive threats
- Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
At $97.72 per share, AECOM trades at 16.5x forward P/E. If you’re considering ACM for your portfolio, see our FREE research report to learn more.
One Stock to Watch:
Boston Scientific (BSX)
One-Month Return: -16.8%
Founded in 1979 with a mission to advance less-invasive medicine, Boston Scientific (NYSE: BSX) develops and manufactures medical devices used in minimally invasive procedures across cardiovascular, urological, neurological, and gastrointestinal specialties.
Why Are We Fans of BSX?
- Existing business lines can expand without risky acquisitions as its organic revenue growth averaged 16.6% over the past two years
- Incremental sales over the last five years have been highly profitable as its earnings per share increased by 26% annually, topping its revenue gains
- Free cash flow margin expanded by 7 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends
Boston Scientific is trading at $76.48 per share, or 21.9x forward P/E. Is now a good time to buy? See for yourself in our comprehensive research report, it’s free.
Stocks We Like Even More
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
